small-cap

One Pharmaceuticals & Biotechnology Stock Trading Near Resistance Levels – PAR

May 15, 2025 | Team Kalkine

Read Time :10 Mins

One Pharmaceuticals & Biotechnology Stock Trading Near Resistance Levels – PAR — Image source: shutterstock

PAR:ASX

Investment Type

Small-Cap

Risk Level

Action

Rec. Price (AU$)

This report is an updated version of the report published on 15 May 2025 at 10:54 AM AEST.

Paradigm Biopharmaceuticals Limited (ASX: PAR)

Paradigm Biopharmaceuticals Limited (ASX: PAR) is a biopharmaceutical company incorporated and domiciled in Australia. The company is engaged in repurposing the drug pentosan polysulfate sodium (PPS) to treat arthralgia driven by injury, inflammation, aging, degenerative disease, infection, or genetics.

Recommendation Rationale – SELL at AUD 0.385

Trading Around Resistance: PAR’s share price surpassed its R1 level recommended on 2 May 2025. Therefore, share price can face resistance at the current levels.
Overvalued Multiples: On a forward 12-month basis – key trading multiples (EV/Sales, and P/BV) is higher than the median of the Healthcare sector.

Reported Losses: The Group recorded a loss of AUD 5.92 million in 1HFY25, highlighting ongoing financial challenges and operational pressures.
Technical Commentary: After a rally, PAR’s stock prices are approaching a significant resistance formed by the December 2024 low, anticipating a potential reversal. Moreover, the stock also appeared a Bearish Engulfing candlestick pattern near the 50-period SMA, providing further support to the previous analysis. Prices are trading between its previous peak and trough, which could serve as resistance and support levels for the stock, respectively
Removal from S&P/ASX Indices: Recently, S&P Dow Jones Indices has announced the results of the March 2025 quarterly review for the S&P/ASX Indices. As part of this review, PAR will be removed from the All-Ordinaries Index. This change was taken effect prior to the opening of trading on 24 March 2025.
Emerging Risks: The company’s success heavily depends on obtaining regulatory approvals for its products. Any delays or failures in gaining these approvals can significantly impact its business. PAR is involved in clinical trials, which are inherently risky. Unsuccessful trials or adverse results can lead to financial losses and delays in product development.

PAR Daily Chart

Considering that the stock has surpassed its R1 level, rally in share price movement, current trading level, and risks associated, the share price can face consolidation at the current levels. Hence, a ‘Sell’ recommendation is given on the stock at the current price of AUD 0.385 (as of 15 May 2025, at 10:15 AM AEST).

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and geopolitical issues prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is neither an indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 15 May 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided have been achieved and is subject to the factors discussed above.

Note 4: Kalkine reports are prepared based on the stock prices captured either from REFINITIV or Trading View. Typically, REFINITIV or Trading View may reflect stock prices with a delay which could be a lag of 25-30 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.

Stop-loss: In general, it is a level to protect further losses in case of any unfavourable movement in the stock prices.

Mid-Cap

Technical Analysis on One NYSE-Listed Uranium Stock- UEC

Mar 13, 2026 Team Kalkine

Small-Cap

One NASDAQ- Listed Semiconductor Stock at Resistance Level- HIMX

Mar 13, 2026 Team Kalkine

Blue-Chip

MQG Scales AUM and Private Credit Capabilities to Drive Growth

Mar 13, 2026 Team Kalkine

Small-Cap

Technical Analysis on Two ASX-Listed Stock – RAU, HRN

Mar 13, 2026 Team Kalkine

Mid-Cap

Technical Analysis on One NYSE- Listed Mining Stock- ERO

Mar 12, 2026 Team Kalkine

Disclaimer-

This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider seeking advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products.

Kalkine is not responsible for, and does not guarantee, the performance of the investments mentioned in this report This report may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services..

Please also read our Terms & Conditions and Financial Services Guide for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.

Past performance is not a reliable indicator of future performance.